|
1
|
Porter KR, McCarthy BJ, Freels S, Kim Y
and Davis FG: Prevalence estimates for primary brain tumors in the
United States by age, gender, behavior, and histology. Neuro Oncol.
12:520–527. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Voss P and Grune T: The nuclear proteasome
and the degradation of oxidatively damaged proteins. Amino Acids.
32:527–534. 2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bladé J, Cibeira MT and Rosiñol L:
Bortezomib: A valuable new antineoplastic strategy in multiple
myeloma. Acta Oncol. 44:440–448. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Adams J, Palombella VJ, Sausville EA,
Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and
Elliott PJ: Proteasome inhibitors: A novel class of potent and
effective antitumor agents. Cancer Res. 59:2615–22. 1999.PubMed/NCBI
|
|
6
|
Yin D, Zhou H, Kumagai T, Liu G, Ong JM,
Black KL and Koeffler HP: Proteasome inhibitor PS-341 causes cell
growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Oncogene. 24:344–354. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kubicek GJ, Werner-Wasik M, Machtay M,
Mallon G, Myers T, Ramirez M, Andrews D, Curran WJ Jr and Dicker
AP: Phase I trial using proteasome inhibitor bortezomib and
concurrent temozolomide and radiotherapy for central nervous system
malignancies. Int J Radiat Oncol Biol Phys. 74:433–439.
2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kong XT, Nguyen NT, Choi YJ, Zhang G,
Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, et al:
Phase 2 study of bortezomib combined with temozolomide and regional
radiation therapy for upfront treatment of patients with newly
diagnosed glioblastoma multiforme: Safety and efficacy assessment.
Int J Radiat Oncol Biol Phys. 100:1195–1203. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Styczynski J, Olszewska-Slonina D,
Kolodziej B, Napieraj M and Wysocki M: Activity of bortezomib in
glioblastoma. Anticancer Res. 26:4499–4503. 2006.PubMed/NCBI
|
|
10
|
Kumar SK, Berdeja JG, Niesvizky R, Lonial
S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, et
al: Safety and tolerability of ixazomib, an oral proteasome
inhibitor, in combination with lenalidomide and dexamethasone in
patients with previously untreated multiple myeloma: An open-label
phase 1/2 study. Lancet Oncol. 15:1503–1512. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kumar SK, Bensinger WI, Zimmerman TM,
Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J,
et al: Phase 1 study of weekly dosing with the investigational oral
proteasome inhibitor ixazomib in relapsed/refractory multiple
myeloma. Blood. 124:1047–1055. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Richardson PG, Baz R, Wang M, Jakubowiak
AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, et al:
Phase 1 study of twice-weekly ixazomib, an oral proteasome
inhibitor, in relapsed/refractory multiple myeloma patients. Blood.
124:1038–1046. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kupperman E, Lee EC, Cao Y, Bannerman B,
Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, et al:
Evaluation of the proteasome inhibitor MLN9708 in preclinical
models of human cancer. Cancer Res. 70:1970–1980. 2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chauhan D, Tian Z, Zhou B, Kuhn D,
Orlowski R, Raje N, Richardson P and Anderson KC: In vitro and in
vivo selective antitumor activity of a novel orally bioavailable
proteasome inhibitor MLN9708 against multiple myeloma cells. Clin
Cancer Res. 17:5311–5321. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gupta N, Diderichsen PM, Hanley MJ, Berg
D, van de Velde H, Harvey RD and Venkatakrishnan K: Population
pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor,
including data from the phase III TOURMALINE-MM1 study to inform
labelling. Clin Pharmacokinet. 6L:1355–1368. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gentile M, Offidani M, Vigna E, Corvatta
L, Recchia AG, Morabito L, Morabito F and Gentili S: Ixazomib for
the treatment of multiple myeloma. Expert Opin Investig Drugs.
24:1287–1298. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gupta N, Zhao Y, Hui AM, Esseltine DL and
Venkatakrishnan K: Switching from body surface area-based to fixed
dosing for the investigational proteasome inhibitor ixazomib: A
population pharmacokinetic analysis. Br J Clin Pharmacol.
79:789–800. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kummar S, Rubinstein L, Kinders R,
Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral
OK, Simpson M, et al: Phase 0 clinical trials: Conceptions and
misconceptions. Cancer J. 14:133–137. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Burger PC, Heinz ER, Shibata T and
Kleihues P: Topographic anatomy and CT correlations in the
untreated glioblastoma multiforme. J Neurosurg. 68:698–704.
1988.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Louis DN, Ohgaki H, Wiestler OD and
Cavenee WK (eds.): WHO Classification of Tumours of the Central
Nervous System. (Revised 4th edition), IARC, Lyon, 2016.
|
|
21
|
Wu W, Lamborn KR, Buckner JC, Novotny PJ,
Chang SM, O'Fallon JR, Jaeckle KA and Prados MD: Joint NCCTG and
NABTC prognostic factors analysis for high-grade recurrent glioma.
Neuro Oncol. 12:164–172. 2010.PubMed/NCBI View Article : Google Scholar
|
